Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Research & Development (2016 - 2025)

Historic Research & Development for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$2.3 billion.

  • Gsk's Research & Development fell 2019.66% to -$2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.0 billion, marking a year-over-year decrease of 1302.75%. This contributed to the annual value of $8.2 billion for FY2024, which is 570.95% up from last year.
  • Per Gsk's latest filing, its Research & Development stood at -$2.3 billion for Q3 2025, which was down 2019.66% from -$2.7 billion recorded in Q2 2025.
  • Gsk's Research & Development's 5-year high stood at -$1.5 billion during Q1 2021, with a 5-year trough of -$8.2 billion in Q4 2024.
  • Moreover, its 5-year median value for Research & Development was -$1.9 billion (2021), whereas its average is -$2.7 billion.
  • Examining YoY changes over the last 5 years, Gsk's Research & Development showed a top increase of 1873.64% in 2022 and a maximum decrease of 24703.54% in 2022.
  • Over the past 5 years, Gsk's Research & Development (Quarter) stood at -$1.9 billion in 2021, then tumbled by 247.04% to -$6.4 billion in 2022, then fell by 19.99% to -$7.7 billion in 2023, then dropped by 6.37% to -$8.2 billion in 2024, then surged by 72.27% to -$2.3 billion in 2025.
  • Its Research & Development stands at -$2.3 billion for Q3 2025, versus -$2.7 billion for Q2 2025 and -$1.8 billion for Q1 2025.